Receiving a denial for Wegovy, Ozempic, Zepbound, or Foundayo is frustrating but not unusual. In 2026, GLP-1 medications are among the most frequently denied prescriptions in the United States. But here is the number that should give you hope: 58% of GLP-1 insurance appeals are ultimately successful, and 41% of peer-to-peer reviews result in approval. This guide is your step-by-step action plan from denial to resolution — or to an affordable alternative.
Why GLP-1 Denials Happen
| Denial Reason | How Common | Appeal Success Rate | What to Do |
|---|---|---|---|
| Plan excludes weight-loss drugs | ~25% of denials | Low (35–40%) | File external review with state commissioner; consider cash-pay alternatives |
| Step therapy not completed | ~28% of denials | High (71%) | Document all prior treatments (lifestyle, metformin, phentermine); submit records |
| Prior authorization missing or incomplete | ~19% of denials | Very high (85%) | Resubmit complete PA with all required documentation |
| BMI below threshold | ~15% of denials | Moderate (54%) | Document comorbidities (hypertension, prediabetes, sleep apnea); use BMI + waist circumference |
| Off-label use | ~13% of denials | Moderate (50%) | Ensure prescription matches an FDA-approved indication for the specific drug |
Step 1: Read Your Denial Letter Carefully
Your denial letter contains critical information:
- Specific denial reason — the exact clinical or administrative reason your claim was rejected
- Appeal deadline — typically 180 days from denial date, but check your plan
- Appeal instructions — where to send your appeal and what format to use
- Clinical criteria — the specific medical criteria the insurer requires for approval
Understanding exactly why you were denied is essential. A denial for "incomplete PA" requires a very different response than a denial for "plan excludes weight-loss medications."
Step 2: File an Internal Appeal
The internal appeal is your first and best shot. Submit within 30 days of denial for fastest results (even though you may have up to 180 days).
What to Include in Your Appeal
- A clinical appeal letter from your prescribing physician explaining medical necessity
- Lab results: A1C, fasting glucose, lipid panel, blood pressure records
- BMI documentation: Current and historical weight, BMI calculation, waist circumference
- Comorbidity documentation: Hypertension, type 2 diabetes, prediabetes, sleep apnea, PCOS, cardiovascular disease
- Prior treatment records: Evidence of failed lifestyle interventions, metformin, phentermine, or other weight-management medications
- Clinical guidelines: References to the Endocrine Society, AGA, or AHA guidelines supporting GLP-1 use
Step 3: Request a Peer-to-Peer Review
If the written appeal is denied, request a peer-to-peer review — a phone call between your doctor and the insurer's medical director. This is where 41% of previously denied claims get approved.
Tips for Your Doctor During Peer-to-Peer
- Be concise and evidence-based — lead with diagnosis, BMI, comorbidities, and failed prior treatments
- Cite specific trial data — STEP trials (semaglutide), SURMOUNT trials (tirzepatide), ATTAIN trials (orforglipron)
- Emphasize cardiovascular risk reduction — SELECT trial showed 20% reduction in MACE events with semaglutide
- Ask the reviewer directly: "What specific criteria would need to be met for approval?"
- Request the call rather than email — verbal communication increases success by approximately 25%
Step 4: External Review
If internal appeals fail, file an external review with your state insurance commissioner. An independent reviewer — not your insurer — evaluates the case.
- File within 180 days of final internal denial
- Use your state's Department of Insurance website for forms
- Include all prior appeal materials, denial letters, and clinical evidence
- External review decisions are legally binding
- Timeline: 45–90 days for a decision
- Success rate for GLP-1 external reviews: approximately 62%
GLP-1 Appeal Timeline
| Step | Timeline | Success Rate | Key Action |
|---|---|---|---|
| Denial received | Day 0 | — | Read letter, note deadline, identify denial reason |
| Internal appeal submitted | Day 1–14 | 58% | Clinical letter, labs, BMI, comorbidities, prior treatments |
| Insurer response | Day 15–45 | — | If denied, request peer-to-peer |
| Peer-to-peer review | Day 30–60 | 41% | Doctor calls insurer's medical director |
| External review filed | Day 60–90 | 62% | File with state commissioner |
| External review decision | Day 90–180 | — | Binding decision |
What to Do While Your Appeal Is Pending
Do not wait months without treatment. Use these bridges:
Manufacturer Savings Programs
- Lilly Zepbound Savings Card: Eligible commercially insured patients may pay as little as $25/month
- Novo Nordisk Wegovy Patient Assistance: Free medication for qualifying low-income patients
- Foundayo (orforglipron) Savings Card: Significant discounts for eligible patients through the manufacturer program
- Novo Nordisk Patient Access Program: Up to 90-day free supply for patients transitioning between coverage
Compounded Semaglutide
Compounded semaglutide is available from 503B compounding pharmacies at $50–$200/month — a fraction of brand-name pricing. Important considerations:
- Not FDA-approved — quality and potency may vary
- Must be prescribed by a licensed provider
- Best obtained through established telehealth platforms that vet their compounding pharmacies
- The FDA has been tightening regulations on compounded GLP-1s — availability may change
Consider Switching Medications
If one GLP-1 is denied, another may be approved:
- Denied Wegovy? Try Zepbound — different mechanism (dual GIP/GLP-1) may have different PA criteria
- Denied Zepbound? Try Foundayo — oral formulation may be on a different formulary tier
- Denied for weight loss? If you have type 2 diabetes, Ozempic may be approved under the diabetes indication
GLP-1 Alternative Options Comparison
| Option | Monthly Cost | Insurance Likelihood | Avg Weight Loss | Best For |
|---|---|---|---|---|
| Wegovy (semaglutide) | $1,000–$1,350 | Moderate (varies by plan) | 15–17% | Obesity with cardiovascular risk |
| Zepbound (tirzepatide) | $1,060–$1,350 | Moderate-high (newer, gaining coverage) | 18–22% | Maximum weight loss |
| Foundayo (orforglipron) | $149–$299 | Growing (added to formularies in 2026) | 10–14% | Oral option, no injections |
| Compounded semaglutide | $50–$200 | Never covered | 10–15% (estimated) | Cost-sensitive patients |
| Phentermine | $20–$50 | Often covered | 5–8% | Short-term use, step therapy |
| Qsymia | $150–$250 | Commonly covered | 10–12% | Patients with migraines or hypertension |
A denial is a speed bump, not a dead end. Most GLP-1 appeals succeed. Start your appeal today, use manufacturer savings as a bridge, and explore alternatives if needed. Compare all your options at MedSwitcher.